NASDAQ:PRCT PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis $80.75 -2.69 (-3.22%) (As of 10:30 AM ET) Add Compare Share Share Today's Range$79.24▼$85.7750-Day Range$56.31▼$83.4452-Week Range$24.83▼$85.81Volume470,585 shsAverage Volume587,978 shsMarket Capitalization$4.15 billionP/E RatioN/ADividend YieldN/APrice Target$70.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get PROCEPT BioRobotics alerts: Email Address PROCEPT BioRobotics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside20.9% Downside$66.00 Price TargetShort InterestBearish10.70% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 8 Articles This WeekInsider TradingSelling Shares$2.40 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.88) to ($1.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.62 out of 5 starsMedical Sector871st out of 924 stocksSurgical & Medical Instruments Industry93rd out of 97 stocks 1.5 Analyst's Opinion Consensus RatingPROCEPT BioRobotics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePROCEPT BioRobotics has only been the subject of 2 research reports in the past 90 days.Read more about PROCEPT BioRobotics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.70% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in PROCEPT BioRobotics has recently decreased by 4.39%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPROCEPT BioRobotics does not currently pay a dividend.Dividend GrowthPROCEPT BioRobotics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRCT. Previous Next 1.8 News and Social Media Coverage News SentimentPROCEPT BioRobotics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for PROCEPT BioRobotics this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for PRCT on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PROCEPT BioRobotics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,399,179.00 in company stock.Percentage Held by Insiders17.40% of the stock of PROCEPT BioRobotics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PROCEPT BioRobotics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($1.88) to ($1.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PROCEPT BioRobotics is -39.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PROCEPT BioRobotics is -39.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPROCEPT BioRobotics has a P/B Ratio of 17.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about PROCEPT BioRobotics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About PROCEPT BioRobotics Stock (NASDAQ:PRCT)PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.Read More PRCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRCT Stock News HeadlinesAugust 14, 2024 | marketbeat.comIs PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?Surgical robotics company PROCEPT BioRobotics Co. (NASDAQ: PRCT) developed the AquaBeam Robotic System for the treatment of benign prostatic hyperplasiaAugust 6, 2024 | marketbeat.comWhy Intuitive Surgical Stock is Dominating the Medical Sector (PRCT)Robotic surgery conjures up futuristic images of automated machines performing surgery on anesthetized human patients in an assembly line. HoweverAugust 22, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.August 22 at 2:58 AM | markets.businessinsider.comBuy Rating Justified: PROCEPT BioRobotics’s Technological Innovation and Market Growth PotentialAugust 22 at 2:58 AM | finance.yahoo.comPROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® TherapyAugust 21 at 7:00 AM | globenewswire.comPROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® TherapyAugust 18, 2024 | ca.finance.yahoo.comPRCT Sep 2024 75.000 callAugust 18, 2024 | ca.finance.yahoo.comPRCT Sep 2024 72.500 callAugust 22, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.August 17, 2024 | ca.finance.yahoo.comPRCT Sep 2024 67.500 putAugust 17, 2024 | ca.finance.yahoo.comPRCT Sep 2024 50.000 callAugust 7, 2024 | ca.finance.yahoo.comPRCT Aug 2024 30.000 putAugust 4, 2024 | finance.yahoo.comPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This YearAugust 3, 2024 | finance.yahoo.comPROCEPT BioRobotics Second Quarter 2024 Earnings: Beats ExpectationsAugust 3, 2024 | markets.businessinsider.comStrong Growth and Robust Performance Justify Buy Rating for PROCEPT BioRoboticsAugust 3, 2024 | markets.businessinsider.comStrong Buy Rating for PROCEPT BioRobotics Amidst Surging Q2 Performance and Market AdoptionAugust 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Alnylam Pharma (ALNY) and Omnicell (OMCL)August 1, 2024 | globenewswire.comPROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA GuidanceSee More Headlines Receive PRCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today8/22/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:PRCT CUSIPN/A CIK1588978 Webwww.procept-biorobotics.com Phone650-232-7200FaxN/AEmployees430Year FoundedN/APrice Target and Rating Average Stock Price Target$66.00 High Stock Price Target$75.00 Low Stock Price Target$37.00 Potential Upside/Downside-20.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105,900,000.00 Net Margins-58.73% Pretax Margin-58.74% Return on Equity-37.85% Return on Assets-26.20% Debt Debt-to-Equity Ratio0.20 Current Ratio7.51 Quick Ratio6.49 Sales & Book Value Annual Sales$176.58 million Price / Sales24.30 Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book17.20Miscellaneous Outstanding Shares51,424,000Free Float42,476,000Market Cap$4.29 billion OptionableOptionable Beta1.00 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Reza Zadno Ph.D. (Age 69)President, CEO & Director Comp: $1.13MMr. Kevin Waters (Age 47)Executive VP & CFO Comp: $680.11kMs. Alaleh Nouri (Age 45)EVP, Chief Legal Officer & Corporate Secretary Comp: $605.84kMr. Hisham Shiblaq (Age 48)Executive VP & Chief Commercial Officer Comp: $645.95kMr. Mohan F. Sancheti (Age 60)Senior Vice President of Operations Mr. Barry TemplinExecutive VP of Technology & Clinical DevelopmentMr. Matthew James Bacso C.F.A.Vice President of Investor RelationsMs. Stacey L. Porter (Age 48)Chief People Officer Mr. Bijesh ChandranSenior Vice President of Regulatory Affairs & Quality AssuranceMore ExecutivesKey CompetitorsAtrionNASDAQ:ATRINano-X ImagingNASDAQ:NNOXInogenNASDAQ:INGNBionano GenomicsNASDAQ:BNGOCuteraNASDAQ:CUTRView All CompetitorsInsiders & InstitutionsDriehaus Capital Management LLCBought 71,930 shares on 8/16/2024Ownership: 0.679%Algert Global LLCBought 27,027 shares on 8/16/2024Ownership: 0.053%Creative PlanningBought 5,267 shares on 8/16/2024Ownership: 0.010%Caxton Associates LPBought 7,033 shares on 8/15/2024Ownership: 0.014%AQR Capital Management LLCBought 5,139 shares on 8/15/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions PRCT Stock Analysis - Frequently Asked Questions How have PRCT shares performed this year? PROCEPT BioRobotics' stock was trading at $41.91 on January 1st, 2024. Since then, PRCT stock has increased by 99.1% and is now trading at $83.44. View the best growth stocks for 2024 here. How were PROCEPT BioRobotics' earnings last quarter? PROCEPT BioRobotics Co. (NASDAQ:PRCT) posted its quarterly earnings data on Thursday, August, 1st. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.02. The firm's revenue for the quarter was up 61.2% on a year-over-year basis. When did PROCEPT BioRobotics IPO? PROCEPT BioRobotics (PRCT) raised $126 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 5,500,000 shares at $22.00-$24.00 per share. Who are PROCEPT BioRobotics' major shareholders? Top institutional investors of PROCEPT BioRobotics include CPMG Inc (1.86%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (1.01%), Blair William & Co. IL (0.81%) and Massachusetts Financial Services Co. MA (0.78%). Insiders that own company stock include Frederic H Moll, Reza Zadno, Morgan Colby Wood, Kevin Waters, Hisham Shiblaq, Alaleh Nouri and Global Investors Lp Viking. View institutional ownership trends. How do I buy shares of PROCEPT BioRobotics? Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRCT) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredThis Crypto Is Set to Explode in AugustWith the 2024 Bitcoin Halving, there's a potential HUGE bull run for altcoins. While everyone's chasing the...Crypto 101 Media | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredSilver Grab of the Decade?In a groundbreaking move, J.P. Morgan now possesses the largest amount of physical silver in recorded history…...Colonial Metals | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThis One stock is all you need...What if you could ignore 99% of the stock market... And retire on just ONE ticker?Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share PROCEPT BioRobotics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
